Aldose reductase inhibitors: the end of an era or the need for different trial designs?

Pfeifer, M A; Schumer, M P; Gelber, D A

Pfeifer, M A; Schumer, M P; Gelber, D A.

Affiliation

Pfeifer MA; Department of Internal Medicine, East Carolina University School of Medicine, Greenville, North Carolina 27858, USA.

Diabetes ; 46 Suppl 2: S82-9, 1997 Sep.

Article in En | MEDLINE | ID: mdl-9285505

Subject(s)

Aldehyde Reductase/antagonists & inhibitors; Diabetic Neuropathies/drug therapy; Enzyme Inhibitors/therapeutic use; Imidazoles/therapeutic use; Imidazolidines; Isoquinolines/therapeutic use; Naphthalenes/therapeutic use; Phthalazines/therapeutic use; Autonomic Nervous System/physiopathology; Humans; Imidazoles/pharmacokinetics; Isoquinolines/pharmacokinetics; Naphthalenes/pharmacokinetics; Phthalazines/pharmacokinetics; Time Factors

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Phthalazines / Aldehyde Reductase / Imidazolidines / Diabetic Neuropathies / Enzyme Inhibitors / Imidazoles / Isoquinolines / Naphthalenes Limits: Humans Language: En Journal: Diabetes Year: 1997 Document type: Article Affiliation country: United States

Search on Google

Add to My VHL

XML

PubMed Links